Clinical Trial Update: Lirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS) [Phase 2]

View source ↗

Summary

Phase 2 trial investigating lirilumab and nivolumab with 5-azacitidine in myelodysplastic syndromes has been terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• 5-Azacitidine (azacitidine)
• lirilumab (lirilumab)
• nivolumab (nivolumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Leukemia | Phase 2 | Status: TERMINATED | Results posted: 2020-01-06